Articles tagged "Rejection"

2020 American Transplant Congress
Is Azathioprine the Right Choice in De Novo Lung Transplantation?
A. Chan¹, B. Sirandas¹, A. Carlson¹, C. Truax¹, B. Clark¹, I. Hall², B. Cahill³, L. Smith¹
¹Pharmacy, University of Utah Health, Salt Lake City, UT, ²Nephrology, University of Utah Health, Salt Lake City, UT, ³Pulmonary, University of Utah Health, Salt Lake City, UT
*Purpose: The antiproliferative of choice in lung transplantation (LT) remains controversial. Limited data exists on azathioprine (AZA) dose reductions or the conversion of AZA to…
2020 American Transplant Congress
Comparison of Basiliximab for Induction Therapy in Kidney Transplant Recipients on Post-Operative Days 0 and 4 versus Post-Operative Days 0 and 3
C. Schardt, R. Yau, A. Burgos, C. Tunwar
Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX
*Purpose: Current dosing recommendations for the administration of basiliximab on post-operative days (POD) 0 and 4 stem from two phase 3 renal transplant studies. Limited…
2020 American Transplant Congress
Impact of Rituximab and Apheresis Techniques in Acute Rejection Rates in ABO Incompatible Living Donor Kidney Transplant
I. Revuelta¹, E. De Sousa-Amorim¹, M. Lozano², D. Cucchiari¹, J. Cid², L. Peri³, E. Palou⁴, M. Musquera³, J. Martorell⁵, J. M. Campistol¹, F. Oppenheimer¹, F. Diekmann¹
¹Renal Transplant Unit, Department of Nephrology and Kidney Transplant, Hospital Clinic, Barcelona, Spain, ²Apheresis and Cellular Therapy Unit, Hospital Clinic, Barcelona, Spain, ³Department of Urology, Hospital Clinic, Barcelona, Spain, ⁴Histocompatibility Lab. Department of Immunology, Hospital Clinic, Barcelona, Spain, ⁵Histocompatibility Lab, Department of Immunology, Hospital Clinic, Barcelona, Spain
*Purpose: ABO incompatibility (ABOi) is a widespread option of living kidney donor transplantation (LKDT). However, controversies in rejection, and death-censored graft survival rates are published,…
2020 American Transplant Congress
Exosomes Containing Kidney Self-Antigens (Collagen Iv, Fibronectin, Perlecan) Predicts Progression of Chronic Immune Injury in Kidney Transplant Recipients
R. Ravichandran¹, Y. Itabashi¹, R. Heilman², A. Jaramillo², D. Ramon², M. Buras², B. Kaplan³, T. Mohanakumar¹, S. Sukumaran Nair²
¹St. Joseph’s Hospital, Phoenix, AZ, ²Mayo Clinic, Phoenix, AZ, ³Baylor Scott and White, Georgetown, TX
*Purpose: We have shown that circulating exosome with lung self-antigens (SAgs) are detectable 1 year prior to chronic lung allograft dysfunction, independent of circulating antibodies.…
2020 American Transplant Congress
Activated CD27⁺CD21^– Subset Dominate the Memory B Cell Response During Antibody-Mediated Rejection of Kidney Allografts
K. Louis¹, E. Bailly¹, C. Macedo¹, M. Marrari¹, M. Yamada¹, P. Randhawa¹, A. Zeevi¹, C. Lefaucheur², D. Metes¹
¹Surgery, University of Pittsburgh, Pittsburgh, PA, ²Inserm UMR 976, Paris, France
*Purpose: The role of alloreactive memory B (mB) cells in the pathogenesis of antibody-mediated rejection (ABMR) is increasingly recognized. Yet, a comprehensive characterization of mB…
2020 American Transplant Congress
Extracellular Vesicles Mediate Endothelial to Mesenchymal Transition and Tubular Senescence in Renal Antibody- Mediated Rejection by Inducing Complement Activation
G. Castellano, R. Franzin, A. Stasi, C. Divella, G. Merlotti, M. Quaglia, F. Sallustio, G. Stallone, V. Cantaluppi, L. Gesualdo
Emergency and Organ Transplantation, University of Bari, Bari, Italy
*Purpose: EVs (Extracellular vesicles), circulating microparticles able to mediate cell-to cell communication, are emerging as pivotal in different kidney diseases. Renal Antibody-Mediated Rejection (AMR) is…
2020 American Transplant Congress
Costimulation Blockade-Based Maintenance Immunosuppression in a Sensitized Nonhuman Primate Kidney Allotransplantation Model
R. Schmitz, Z. W. Fitch, P. M. Schroder, A. Y. Choi, M. Manook, J. Yoon, J. Kwun, S. J. Knechtle
Department of Surgery, Duke University Medical Center, Durham, NC
*Purpose: Sensitized transplant recipients represent a challenging population in part due to the presence of donor-specific antibodies (DSA), which increase the risk of antibody-mediated rejection.…
2020 American Transplant Congress
Can Cxcr3⁺Cd62l^–Cd4⁺ T Cells Serve as Early Warning Sentinels for Subclinical Rejections after Vascularized Composite Allotransplantation (vca)?
M. Kim¹, D. Fisher¹, J. Loo¹, J. Skitzki¹, E. Repasky²
¹Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, ²Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
*Purpose: New microsurgical techniques and powerful immunosuppressive drugs have made it possible for severely injured patients to receive VCA to replace limbs, hands, or faces,…
2020 American Transplant Congress
Comparison of Clinical Characteristics and Outcomes of Early Antibody-Mediated Rejection and Late Antibody-Mediated Rejection after Kidney Transplantation
G. Chen, Z. Wu, C. Wang, X. Liu, Q. Li, L. Chen
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
*Purpose: Antibody-mediated rejection(AMR) is a major risk factor for graft loss after kidney transplantation. Some AMR appeared within 6 months after kidney transplant, that we…
2020 American Transplant Congress
Comparison of Reduced-Dose and Labeled-Dose Belatacept Conversion with Immediate or Early Tacrolimus Withdrawal in Kidney Transplant Recipients without Maintenance Corticosteroids
H. Kuzaro¹, A. R. Shields², M. Cuffy², E. S. Woodle¹, K. Pembaur², S. Safdar², S. Huang², G. Krisko², S. Raabe², R. Parks², J. Kremer²
¹U Cincinnati, Cincinnati, OH, ²The Christ Hospital, Cincinnati, OH
*Purpose: A primary reason for conversion from tacrolimus (TAC) to belatacept (BELA) is to avoid nephrotoxicity. Previous published experiences with BELA-conversion regimens have shown increased…